Misdiagnosis of Still's Disease High fever, strange rashes, scary labs often lead to a consideration of Still's disease (AOSD or systemic JIA). Yet the dramatic onset of a systemic disorder may overlap with another, and possibly as rare, systemic disorder that should not be https://t.co/mCbNBAt9T5

Tune in for an expert conversation on the latest data from SELECT-SWITCH, including discussion about the EULAR 2026 post hoc analysis of primary and secondary TNFi nonresponders. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Fkdgk1T7qm https://t.co/W1jrlU3R5b

Risk of Venous Thromboembolism in Rheumatoid Arthritis RA confers a 50–100% excess risk of venous thromboembolism (VTE) compared with the general population, with adjusted hazard/odds ratios ranging from 1.3–2.2 across large cohort studies (Vojinovic, Askling, Antovic; https://t.co/IsS6vqo6vU

Latest #s: EHR estimates from 6 large US medical systems, estimated prevalence of autoimmune Dz (AID) to be >15 million (4.6% US population); 34% have > 1 AID. Women have 2x risk. Sex ratio of 1.7:1 F:M. https://t.co/tfSCpRqHbY https://t.co/VckjIoGOaa

JAMA: Review of Shoulder Pain JAMA Internal Medicine (Haas et al, 2026) has published a clinical overview to the approach, diagnosis and management of Shoulder Pain. https://t.co/xYSahFksx9 https://t.co/kTIml2mD6k

Joint Pain Prevalence is not Declining A current report from the national NHIS survey shows that over half of US adults diagnosed with arthritis reported moderate to severe joint pain. https://t.co/zq7pGaZO72 https://t.co/kvco72v5IZ

MASLD - Spanish review of 330 pts (101 psoriasis, 127 PsA, 102 controls) found metabolic-dysfunc-assoc steatotic liver Dz in 48% PsO, 32% PsA, 9% controls (p < 0.001). FibroScan tended higher in PsO 6.01 PsA 5.1 vs 4.9 controls https://t.co/wPxbLwVlOW https://t.co/ZtqYX5HPZa

Childhood vs Adult onset SLE? Retro Australian Lupus Registry study of 519 SLE pts (68/13% w/ cSLE) found childhood onset had signif more damage (SDI≥1 53 vs 40%; renal Dz 62 vs 37%), more Dz activity, less LLDAS-50 (36% vs 51%) https://t.co/ttBRtSVl5n https://t.co/hoN1t16Za3

RHEUMATOLOGIST Survey Q> For Sjogrens disease, what therapy do you most commonly use? Click here: https://t.co/XJEsqoSlbn https://t.co/FvlOqwl2aD

Systematic review of targeted Rx for lupus nephritis during pregnancy (2000-25). HCQ & AZA are cornerstone good Rx. Acceptable: tacrolimus, ASA. MMF is TERATOGENIC-AVOID! Not Enuf data; Voclosporin, obinutuzumab, Anifrolumab https://t.co/otO9nMHHuO https://t.co/1hLysZLJnG

Nonrigid lumbar belts for nonspecific low back pain actually work! Multicenter French trial enrolled 168 nsLBP pts - belt group had better wk 12, lower pain scores andless need for back pain medication. https://t.co/zgRclsoAR8 https://t.co/9HVwuE1YLz

Italian SPRING cohort of #SSc pts found only 5.3% (of 1689 pts) without the typical scleroderma pattern on nailfold change by NVC. They had milder dz, with less vascular dz (pitting scars 33 vs 48%), telangiectasias (52 vs 74%), calcinosis 3.4 vs 12%) & higher DLCOs at 12, 24, https://t.co/AoNAhVYfII

Retrospective Medicare comparison 450 paired #PMR cohorts Rx w/ IL-6 inhib or csDMARDs. At 1 yr, IL-6i pts (vs csDMARD) had signif more GC D/C (adj HR 1.28) or minimal GC use (<3mg/d) (aHR 1.28). Hosp. infxn 2X higher in IL-6i (12.2 vs 5.7 per 100 PY) in year 1, but not year 2 https://t.co/YgqLjD9nvM

Prolonged exposure to targeted Rx in #SpA not assoc w/ increased cancer risk. French claims study 56,591 SpA pts- 1,224 CA (1,029 solid, 116 Heme). TNFi, IL17i, IL12/23i, IL23i, JAKi Exposure >6 vs ≤6 mos assoc w/ lower CA (HR 0.86; 0.75-0.99); signif for Heme (HR 0.65), not https://t.co/rHAa0CkAjT

EU Finalizes Tavneos Withdrawal - The European Commission has officially revoked the marketing authorization for Tavneos (avacopan), finalizing a process that began with regulators flagging the drug's pivotal trial data as "incorrect and misleading." The EC issued its legally https://t.co/jgysiV1hyX